iodipamide meglumine

Trade name: cholografin meglumine

Small moleculeapproved

Approved

Apr 27, 1954

Iodipamide is used as a contrast agent for cholecystography and intravenous cholangiography. Following intravenous administration of Cholografin Meglumine, iodipamide is carried to the liver where it is rapidly secreted. The contrast medium appears in the bile within 10 to 15 minutes after injection, thus permitting visualization of the hepatic and common bile ducts, even in cholecystectomized patients. Iodipamide (Cholografin Meglumine) is indicated for intravenous cholangiography and cholecystography as follows: (a) visualization of the gallbladder and biliary ducts in the differential diagnosis of acute abdominal conditions, (b) visualization of the biliary ducts, especially in patients with symptoms after cholecystectomy, and (c) visualization of the gallbladder in patients unable to take oral contrast media or to absorb contrast media from the gastrointestinal tract. The biliary ducts are readily visualized within about 25 minutes after administration, except in patients with impaired liver function. The gallbladder begins to fill within an hour after injection; maximum filling is reached after two to two and one-half hours. Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these iodinated organic compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. Iodipamide's primary excretion through the hepato-biliary system and concentration in bile allows visualization of the gallbladder and biliary ducts. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1950s

  1. Apr 27, 1954

    Bracco — Earliest FDA Approval

  2. Apr 27, 1954

    Bracco — NDA Secondary Org

  3. Apr 27, 1954

    Bracco — NDA Organization

Indications

Mechanism of action

Combination products

Approval history

  • approvedApr 27, 1954

Chemistry & pharmacology

Loading structure…

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(CCCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I
Mol. weight
1530.19 g/mol
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • 3,3'-(adipoyldiimino)bis(2,4,6-triiodobenzoic acid)
  • 3,3'-(adipoyldiimino)bis(2,4,6-triiodobenzoic acid)
  • adipiodon
  • adipiodona
  • adipiodona
  • adipiodone
  • adipiodone
  • adipiodone
  • adipiodone
  • adipiodone
  • adipiodone meglumine
  • adipiodone meglumine injection
  • adipiodone meglumine injection
  • adipiodonum
  • adipiodonum
  • biligrafin
  • cholografin
  • cholografin
  • cholografin
  • cholografin meglumine
  • cholografin meglumine
  • cholografin meglumine
  • cholografin meglumine
  • cholografin meglumine
  • cholografin sodium
  • cholografin sodium
  • cholografin sodium
  • endografin
  • iodipamic acid
  • iodipamide
  • iodipamide
  • iodipamide
  • iodipamide
  • iodipamide
  • iodipamide
  • iodipamide meglumine
  • iodipamide meglumine
  • iodipamide meglumine
  • iodipamide meglumine
  • iodipamide meglumine
  • iodipamide meglumine
  • iodipamide methylglucamine injection
  • iodipamide methylglucamine injection
  • iodipamide sodium
  • iodipamide sodium
  • iodipamide sodium
  • iodipamide sodium
  • meglumine adipiodone
  • meglumine iodipamide
  • methylglucamine iodipamide
  • methylglucamine iodipamide
  • methylglucamine iodipamide
  • radioselectan

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
BraccoFor profitNDA2Apr 27, 1954
BraccoFor profitNDAApr 27, 1954